Clinical Trials Browser

Pathologic Complete Response, Histiocytosis, Langerhans-Cell, Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Philadelphia Chromosome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02613026 2015-11-24

Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer

Phase 3 Completed

104 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms

NCT01433926 2011-09-14

LongHer

Completed

114 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms

NCT01203267 2010-09-16

Weekly Paclitaxel Plus Carboplatin in Preoperative Treatment of Breast Cancer

Phase 2 Completed

108 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms

NCT00343720 2008-03-13

Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy

Phase 2 Completed

Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT00378222 2006-09-19

Autologous Transplantation for Multiple Myeloma

Phase 3 Completed

324 enrolled

Plasma cell

Pathologic Complete Response, Multiple Myeloma

Clinical Trials

Impact Of Metformin In Rectal Cancer Patients

QUAZAR AML-001

Intratumoral and Peritumoral Habitat Radiomics of MRI Predict Pathologic Complete Response to Neoadjuvant Chemoimmunotherapy in Oral Squamous Cell Carcinoma

Study on the Applicability of CCR Criteria in Rectal Cancer

WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)

PALACE-2

Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer

FLYSYN-101

PTC Guiding Neoadjuvant Treatment in Breast Cancer

PRISM

Assessment of Complete Response MRI Criterion After Neoadjuvant Therapy in Locally Advanced Rectal Cancer

TRUS-FNA For The Prediction Of pCR After Neoadjuvant Treatment In Rectal Cancer

GRECCAR6

Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)

RPAI-pCR

Diagnosing Pulmonary Aspergillosis in Patients With Hematological Malignancies: A Multicentre Prospective Evaluation of an Aspergillus PCR Assay and a Galactomannan ELISA in Bronchoalveolar Lavage Samples

5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer

Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patients With Acute Myeloid Leukemia (AML)

Predictive Factors of Disease-free Survival After Complete Pathological Response to Neoadjuvant Radiotherapy in Rectal Adenocarcinoma

TNBCbrazil

HT01

Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies

Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer

LongHer

Weekly Paclitaxel Plus Carboplatin in Preoperative Treatment of Breast Cancer

Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy

Autologous Transplantation for Multiple Myeloma